Literature DB >> 34152626

Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease.

Yu-Jie Zhou1,2, Feng Gao1, Wen-Yue Liu1, Grace Lai-Hung Wong3, Sanjiv Mahadeva4, Nik Raihan Nik Mustapha5, Xiao-Dong Wang1, Wah-Kheong Chan4, Vincent Wai-Sun Wong3, Ming-Hua Zheng1.   

Abstract

BACKGROUND: Recently, Papatheodoridi et al proposed to refine the Baveno VI elastography dual-cutoffs and introduce an algorithm for the detection of compensated advanced chronic liver disease (cACLD) in asymptomatic European patients with chronic liver diseases. AIMS: To validate the performance of the dual-cutoffs (8/12 kPa) and the proposed algorithm to identify patients with cACLD in three well-characterised Asian nonalcoholic fatty liver disease (NAFLD) cohorts.
METHODS: We included 830 patients with biopsy-proven NAFLD. Liver stiffness was measured using transient elastography (FibroScan).
RESULTS: cACLD was found in 21.8% of patients. Compared with the original Baveno VI elastography criteria (10/15 kPa), the new cutoffs showed a comparable specificity and a higher sensitivity for identifying cACLD. We developed a simplified risk model incorporating age, liver stiffness value, and platelet count, which outperformed liver stiffness measurement alone in two Chinese cohorts (P = 0.001), and was further validated in a Malaysian cohort (P = 0.04). Overall, the "two-step" screening of cACLD improved classification rates from 73.5% by the original dual-cutoffs to 86.7%. Notably, usage of our simplified risk model resulted in significantly lower false-negative rate than the refined screening approach by Papatheodoridi et al (27.1% vs 41.4%; P = 0.01).
CONCLUSIONS: The dual elastography cutoffs of 8 and 12 kPa are more appropriate to identify cACLD in Asian patients with NAFLD. In combination with a simplified risk model in unclassified patients, the two-step approach showed a classification rate of about 85%.
© 2021 John Wiley & Sons Ltd.

Entities:  

Year:  2021        PMID: 34152626     DOI: 10.1111/apt.16487

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria.

Authors:  Anshuman Elhence; Abhinav Anand; Sagnik Biswas; Manas Vaishnav; Rajni Yadav; Prasenjit Das; Rajesh Panwar; Sandeep Agarwal; Shivanand Gamanagatti; Ramesh Kumar
Journal:  Dig Dis Sci       Date:  2022-06-07       Impact factor: 3.199

2.  Gut bacteria alleviate smoking-related NASH by degrading gut nicotine.

Authors:  Bo Chen; Lulu Sun; Guangyi Zeng; Zhe Shen; Kai Wang; Limin Yin; Feng Xu; Pengcheng Wang; Yong Ding; Qixing Nie; Qing Wu; Zhiwei Zhang; Jialin Xia; Jun Lin; Yuhong Luo; Jie Cai; Kristopher W Krausz; Ruimao Zheng; Yanxue Xue; Ming-Hua Zheng; Yang Li; Chaohui Yu; Frank J Gonzalez; Changtao Jiang
Journal:  Nature       Date:  2022-10-19       Impact factor: 69.504

3.  acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.

Authors:  Xi-Xi Wu; Kenneth I Zheng; Jérôme Boursier; Wah-Kheong Chan; Yusuf Yilmaz; Manuel Romero-Gómez; Mohamed El Kassas; Giovanni Targher; Christopher D Byrne; Zhi-Ming Huang; Ming-Hua Zheng
Journal:  EClinicalMedicine       Date:  2021-10-01

Review 4.  Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.

Authors:  Wah-Kheong Chan; Soek-Siam Tan; Siew-Pheng Chan; Yeong-Yeh Lee; Hoi-Poh Tee; Sanjiv Mahadeva; Khean-Lee Goh; Anis Safura Ramli; Feisul Mustapha; Nik Ritza Kosai; Raja Affendi Raja Ali
Journal:  J Gastroenterol Hepatol       Date:  2022-02-08       Impact factor: 4.369

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.